Immunome, Inc. (IMNM) - Stock Analysis
Last updated: Jun 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash Cushion ⢠Operating Losses ⢠Cash Burn IMNM's balance sheet is exceptionally strong, but the stock remains challenged by negligible revenue, persistent losses, and ongoing cash burn.
Price Behavior
Key Price Behavior Insights: ⢠Broken support ⢠Failed rebound ⢠Oversold bounce Support Level: $19.66-$19.68 Resistance Level: $20.80-$21.00 Over the last month, IMNM has broken into a short-term downtrend, lost support near $19.66-$19.68, and remains oversold with only a bounce above $20.80-$21.00 likely to improve the trend. ŕ°
Sentiment & News
Key News Insights: ⢠Pipeline Progress ⢠Investor Visibility ⢠Hiring Momentum Immunome's recent headlines highlight steady pipeline progress, investor engagement, and continued hiring, led by detailed Phase 3 varegacestat data and no major negative developments.
AI Summary
IMNM has shifted from a cash-rich but unproven biotech to a funded near-term catalyst story, but with no revenue base and a broken chart, it remains a hold/watch until varegacestat's FDA/Phase 3 progress reduces binary risk or the company risks continued burn and dilution without a re-rating.
Description
Immunome, Inc. is a biopharmaceutical firm that discovers and develops monoclonal antibody therapeutics for oncology and infectious diseases. Its lead oncology candidate, IMM-ONC-01, targets the IL-38 tumor-derived immune checkpoint implicated in tumor immune evasion, and the company also maintains an antibody cocktail program for SARS-CoV-2. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | IMNM | Immunome, Inc. | Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity. | Closed | +12.9% |